Marla Keller, M.D.
News — June 3, 2024—(BRONX, NY)—, a national leader in academic medicine and in clinical and translational research and training, has been appointed executive dean at . In this role, Dr. Keller will work closely with , the Marilyn and Stanley M. Katz Dean at Einstein, other executive leaders at the College of Medicine and , and the Board of Trustees to achieve the vision for the institution. As Einstein’s second most senior officer, she will drive strategic planning for the College of Medicine and provide guidance across all academic and research programs.
Dr. Keller has served Einstein with great distinction over the past 17 years. She is currently the director of the NIH-funded at Einstein and Montefiore and the interim senior associate dean for clinical and translational research. She previously served as vice chair of research in the department of medicine.
“Dr. Keller’s accomplishments at Montefiore Einstein and on the national stage have clearly demonstrated her effective and collaborative leadership, research and administrative acumen, dedication to innovation, and commitment to diversity, equity, and inclusion,” said Dr. Tomer, who is also chief academic officer at Montefiore Einstein. “Her appointment is a crucial step in moving Einstein forward into a new era of excellence and ensuring the ongoing success of our enterprise.”
Dr. Keller was selected by a search committee after a thorough internal search. She will assume her new role on July 1, 2024, succeeding Edward R. Burns, M.D., who has provided exemplary and steadfast leadership in this position since 2000.
As executive dean, Dr. Keller will be responsible for supporting clinical, translational, and basic science research, as well as the educational and academic operations. She will also direct the research enterprise, providing guidance and resources for research education and training, fostering new and interdisciplinary research initiatives and collaborations, and implementing all regulations and policies. She will work closely with department chairs and center directors to fund and spur new research, strategically recruit, retain, and mentor faculty, and expand opportunities for scientific discovery with the office of biotechnology and business development.
“Guided by and a new strategic plan, I will work tirelessly with Dean Tomer, his leadership team, department chairs, and center directors to enhance basic science and clinical research, improve research operations, integrate Einstein’s and Montefiore’s clinical and translational research programs, and bolster our education initiatives,” said Dr. Keller.
As vice chair of research for the department of medicine, Dr. Keller oversaw a robust research portfolio of more than 100 principal investigators. NIH funding increased significantly and a formal research compensation plan was developed for the department. She streamlined research operations, increasing the number of clinical trials to more than 200 across 14 divisions. One of her most important initiatives was creating a physician-scientist pathway to support faculty in becoming independently funded investigators. During her seven-year tenure, the department had 37 K (early career) awardees, of which 23% are from groups historically underrepresented in medicine, and 43% transitioned to R (independent research) funding. She also co-founded a junior faculty mentoring program and led the department’s COVID-19 treatment task force.
On the national level, she served as a member of the U.S. Department of Health and Human Services panel on HIV treatment guidelines and the NIH COVID-19 treatment guidelines panel, helping to shape protocols for the country. She is a fellow of the Infectious Diseases Society of America and a member of the HIV Medical Association.
Dr. Keller’s research has focused on prevention of HIV in women using biomedical interventions, improving cervical cancer screening practices, and the treatment of COVID-19, resulting in nearly 100 publications.
After earning an M.D. from New York University School of Medicine, Dr. Keller completed an internal medicine residency at Beth Israel Hospital in Boston and an infectious diseases fellowship at Beth Israel/Brigham & Women’s Hospital combined program. She was recruited to Montefiore Einstein in 2007 after spending nine years on the faculty at the Mount Sinai School of Medicine.
“The executive dean position requires leadership, sensitivity, creativity, collaboration, innovation, and dedication and I am confident, given her abilities and experience, that Dr. Keller will excel in her new role,” said Dr. Tomer.
***
About Albert Einstein College of Medicine
is one of the nation’s premier centers for research, medical education and clinical investigation. During the 2023-24 academic year, Einstein is home to 737 students, 209 students, 124 students in the , and approximately 239 . The College of Medicine has more than 2,000 full-time faculty members located on the main campus and at its . In 2023, Einstein received more than $192 million in awards from the National Institutes of Health. This includes the funding of major at Einstein in cancer, aging, intellectual development disorders, diabetes, clinical and translational research, liver disease, and AIDS. Other areas where the College of Medicine is concentrating its efforts include developmental brain research, neuroscience, cardiac disease, and initiatives to reduce and eliminate ethnic and racial health disparities. Its partnership with , the University Hospital and academic medical center for Einstein, advances clinical and translational research to accelerate the pace at which new discoveries become the treatments and therapies that benefit patients. For more information, please visit , follow us on , , , , and view us on .
RSS